Historical record - last NADAC publication: 8/22/2018

Product Information

ABILIFY 30 MG TABLET is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $40.4383 per EA under NDC 59148001135. Its NADAC has been published 287 times since Nov 28, 2013.

The High Outlier badge above means this manufacturer's average price in the ARIPIPRAZOLE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

ABILIFY 30 MG TABLET

ARIPIPRAZOLE
$40.4383per EA
High Outlier

Strength

30 mg/1

NDC

59148001135

Classification

Brand

Dosage Form

TABLET

Route

ORAL

Last Updated

8/22/2018

Active Ingredients

ARIPIPRAZOLE

Approval Type

New Drug (NDA)

FDA Application

NDA021436

On Market Since

11/15/2002

Pharmacological Classes

Price Statistics

The NADAC for ABILIFY 30 MG TABLET has been published 287 times since Nov 28, 2013, and over the history we have for it it has risen 31.5%. The table below summarizes its recorded NADAC range and movement.

Current price$40.4383 per EA
All-time high$40.9832 (Oct 14, 2015)
All-time low$30.7488 (Nov 28, 2013)
Median price$40.5018
Average price$39.4487
Largest weekly change+16.0% (Jan 8, 2014)
Weeks tracked287
Tracking sinceNov 28, 2013

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

0.0%

1Y

0.0%

3Y

0.0%

5Y

0.0%

All

+31.5%

Generic Alternatives

The matcher finds 2 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 2 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 100% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Frequently asked questions

What is the NADAC price of ABILIFY 30 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for ABILIFY 30 MG TABLET, manufactured by Otsuka America Pharmaceutical Inc., is $40.4383 per EA (NDC 59148001135), effective May 22, 2019.

How has the price of ABILIFY 30 MG TABLET changed over time?

Over the history we have for it, the NADAC for ABILIFY 30 MG TABLET has risen 31.5%. It has been tracked across 287 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for ABILIFY 30 MG TABLET?

Since Nov 28, 2013, the NADAC for ABILIFY 30 MG TABLET has ranged from a low of $30.7488 (Nov 28, 2013) to a high of $40.9832 (Oct 14, 2015), with a median of $40.5018 per EA.

Are there cheaper alternatives to ABILIFY 30 MG TABLET?

Yes. 2 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, ARIPIPRAZOLE 30 MG TABLET, is $0.1734 per EA — about 100% below ABILIFY 30 MG TABLET.

Who manufactures ABILIFY 30 MG TABLET?

ABILIFY 30 MG TABLET (NDC 59148001135) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.